JG
IMVT icon

Joel Greenblatt’s Immunovant IMVT Stock Holding History

Joel Greenblatt’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.16M Buy
+30,100
New +$917K ﹤0.01% 1315
2023
Q4 		– Sell
-5,527
Closed -$212K – 1379
2023
Q3 		$212K Buy
+5,527
New +$125K ﹤0.01% 1221

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Joel Greenblatt's IMVT Position: Q2 2026 in Review

Joel Greenblatt opened a new position in Immunovant (IMVT) in Q2 2026: 30,100 shares worth $1.16M. The stake represents ﹤0.01% of the portfolio and ranks #1315 among its holdings. This is a return to the name: Joel Greenblatt previously reported a position in IMVT as recently as Q3 2023.

Joel Greenblatt first reported a position in IMVT in Q3 2023 and has held it in 2 quarters since. 224 funds tracked by Wall St. Rank hold IMVT as of Q2 2026.

  • Joel Greenblatt held 30,100 shares of Immunovant worth $1.16M as of Q2 2026.
  • Immunovant was a new Joel Greenblatt position in Q2 2026.
  • Immunovant made up ﹤0.01% of Joel Greenblatt's portfolio in Q2 2026, its #1315 holding.
  • Joel Greenblatt first reported a position in Immunovant in Q3 2023 and has held it in 2 quarters since.
  • 224 funds tracked by Wall St. Rank held Immunovant as of Q2 2026.

Based on Gotham Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.